Podcasts about Cystic fibrosis

Submit your CPR Report ⁠⁠⁠here⁠⁠⁠. Get a call from Dr. Zeeshan or Nurse Brittany fill out form ⁠⁠⁠here⁠⁠⁠!⁠⁠⁠https://docs.google.com/forms/d/e/1FAIpQLSeAO_cq5OE6ONYgDFSz0HHrUqKt2Nk1JfC-3D7eXUl8LlzGdg/viewform⁠⁠⁠www.nclexhighyield.com⁠⁠⁠Our Self-Paced Online Videos are on sale for $44.99 and has updated notes, videos, and practice questions! ⁠⁠⁠You can join at https://nclexhighyieldcourse.com/p/full-nclex-course7

Tom opens this week's livestream with a reminder about the New Biology Experience at Polyface Farm (June 2026).-Registration is still open, and Tom invites viewers to join for a weekend of talks, music, good food, and reconnecting with friends and community.New Biology Experience link here.Highlights from this session include:-Tom revisits a widely shared “photograph of an atom” and presents it as an audience intelligence test, pointing out a contradiction: if the nucleus were the size of a pinhead, electrons should be about a mile away, not the inch-scale distance depicted in the image.-A discussion on how mathematics is often used to imply the existence of things that have never been directly demonstrated, illustrated with his analogy of a hypothetical “bucket made of fairy dust.”-Tom examines a case where DNA testing suggested a woman was not the mother of children she had given birth to, using the example to question the idea that DNA testing is “100% foolproof” and to discuss how scientific claims can become unfalsifiable.-A deep dive into the claim that cystic fibrosis is a proven genetic disease, including a review of foundational literature and the assumptions behind the idea that genes code for specific proteins.-A critique of research on human metapneumovirus (HMPV), focusing on how viruses are said to be “isolated” in cell culture and highlighting logical contradictions when cytopathic effects are rarely observed.-Tom reflects on a recent interview discussing HPV vaccination campaigns, emphasizing the importance of distinguishing intentions from strategies when debating health policies. He argues that discussions should focus on evidence and factual claims, rather than accusations about motives.Tom closes the session by encouraging viewers to stay focused on clear reasoning, evidence, and careful questioning of scientific claims. Support the showWebsites:https://drtomcowan.com/https://www.drcowansgarden.com/https://newbiologyclinic.com/https://newbiologycurriculum.com/Instagram: @TalkinTurkeywithTomFacebook: https://www.facebook.com/DrTomCowan/Bitchute: https://www.bitchute.com/channel/CivTSuEjw6Qp/YouTube: https://www.youtube.com/channel/UCzxdc2o0Q_XZIPwo07XCrNg

A Kiwi woman has made history becoming the first New Zealander with Cystic Fibrosis to complete an Ironman. Kirsty Parsons spoke to Ingrid Hipkiss.

Over the course of his career, Dr. Michael Welsh has seen cystic fibrosis transform from terminal to highly treatable. On this episode of Talk of Iowa, we listen back to Charity Nebbe's conversation with Dr. Welsh of the Carver College of Medicine at the University of Iowa, who has been studying and treating Cystic Fibrosis for nearly 50 years. Dr. Welsh was awarded the 2025 Canada Gairdner International Award for his work on cystic fibrosis. Then, we hear about the Homestead Folk Art Museum in the Amana Colonies. (This show was originally produced on June 5, 2025.)

In this episode of the HR Like a Boss podcast, John interviews HR leader Tammy Luby, who shares her journey in human resources, her impactful experiences, and her unique presentation titled 'Stop Flicking Chickens.' Tammy discusses the purpose of HR, the importance of making a difference in people's lives, and her aspirations to turn her presentation into a book. The conversation emphasizes the need for positivity and mentorship in HR, as well as the importance of looking beyond daily challenges to create a meaningful impact.ABOUT TAMMY LUBYTammy Luby, MBA, SPHR, AI+HI, & SHRM-SCP Director of Human Resources, Riverhead Building Supply Adjunct Professor & Faculty Team lead, Southern New Hampshire University. Meet Tammy Luby, a dynamic HR professional with over 25 years of experience in the field. With an MBA and certifications as a Senior Professional in Human Resources (SPHR) and Senior Certified Professional (SHRM-SCP), Tammy is a powerhouse of knowledge and expertise. She is fluent in the entire lifecycle of the employment process, including multi-state and union environments. Tammy is not just an HR generalist; she is a proactive agent of change, certified in AI+HI, and known for her support of HR initiatives on Long Island. Often referred to as the HR ambassador of the East End, Tammy is deeply involved in professional groups to advance the HR profession and ethics. She is passionate about building the workforce of the future by engaging students in high schools, colleges, and technical/trade schools through presentations, tours, and workshops. In addition to her role at Riverhead Building Supply, Tammy co-founded and chairs The HR East End Circle, a Human Resource round table based out of Eastern Long Island, NY. She is also a newly appointed member of the Board of Directors with the Long Island Chapter of The Society of Human Resource Management (SHRM). Tammy's volunteer work includes contributions to the United Way, Cystic Fibrosis, American Heart Association, and The American Cancer Society. She is proud to be part of a company committed to a respectful workplace, honesty, and integrity. When she's not shaping the future of HR, you can find Tammy sharing her knowledge as an adjunct professor at Southern New Hampshire University or leading the HR faculty.

I have spent my career around some of the world's most focused individuals, but Kristan Hawkins brings a level of grittiness and fearlessness that is truly in a league of its own. As the president of Students for Life, Kristan isn't just an activist; she is a mother of four and a "revolutionary" for the most vulnerable among us. In this powerful episode, we go far beyond the viral debate clips to discuss the heart of her mission. Kristan gets incredibly real about: Her "total crap day" in San Antonio that led to saving a life—and meeting Baby Mercer. The psychology of conflict and why she believes change only happens when you produce friction. The shocking truth about eugenics in modern medical systems and the "billion-dollar pharmaceutical industry". Raising a family with Cystic Fibrosis and the radical choice to choose life even when the numbers are against you. Whether you agree with her or not, you cannot deny the passion and the "grittiness" Kristan brings to this conversation. We discuss why she refuses to be a people-pleaser and how she finds the strength to keep standing tall—even when the threats and vitriol come from both sides of the aisle. Connect with Kristan Hawkins: Instagram: @kristan_hawkins Website: studentsforlife.org Sponsors: PreBorn: Provide one life-saving ultrasound for just $28 at https://preborn.com/sage Cowboy Colostrum: Get 25% Off Cowboy Colostrum with code SAGE at https://www.cowboycolostrum.com/SAGE

We're going deep today, Slushies. Kathy and Tobi school us on the origin of the word “podcast” with its roots in both early Apple technology and agricultural lingo (think broadcast of seeds). In this episode we're broadcasting our appreciation for poems by Erin Evans. We admire Evans' sound work and her ability to craft powerful lines with plain language. In the first poem, the poet's confrontation of medical jargon reminds Marion of Whitman's poem When I Heard the Learn'd Astronomer. An encounter between patient and doctor in Evans' poem underscores the difference between learning and knowing that recalls Leslie Jamison's book of essays, The Empathy Exams.    The second poem's Japanese title evokes the film Rashomon for Jason, who takes issue with the notion that our writerly imaginations are limited only to the words available in our own language. Schadenfreude, anyone? We're digging the close focus on language in these poems. Marion appreciates that the poem elevates a term she initially passed off as one from pop culture wellness. Meanwhile we conflate our Wabi-sabi with our kintsugi and poet Ross Gay with the poet Ross White (who is the actual originator of the gas station sushi theory). But don't let our mistakes keep you from experiencing Evans' powerful endings.   Slushies, if you're attending AWP in March, please stop by and see us at the book fair. We'll be at table 1272. We'd love to see you in person. Thanks, as always, for listening!   At the table: Tobi Kassim, Jason Schneiderman, Kathleen Volk Miller, Marion Wrenn, Lisa Zerkle, and Lillie Volpe (sound engineer)  Author Photo:    Author Bio: Erin Evans was diagnosed with Cystic Fibrosis when she was one year old. Her work is greatly influenced by her experience living with chronic illness. She has had poems published in Defunct, Revel, A Mouthful of Salt, and Nimrod-International Journal, which awarded her its Francine Ringold Award for New Writers. Her work was chosen by Kwame Dawes for his American Life in Poetry column. She lives in Vermont with her beautiful and brilliant kids. Exacerbation She says the word quickly looking down at my file   then back at the x-ray clipped against the glowing box.   My scarred and patchy lungs, and all their flaws  on display, almost make me blush.   Embarrassed that I couldn't do any better, have been better. I focus instead    on the soft ribbons of my ribcage that fan like ghost hands   lit up for Halloween. Again, she says it,   looking at me now  as she sits on the round rolling chair   and reaches for her stethoscope. Exacerbation, which I finally looked up   after years and years of hearing it, simply means a worsening.   But she was taught not to state  the obvious, to disguise the truth   in the language of textbooks, and lectures, years of learning   how best to look right through someone. And I was taught to breathe in when I was told,   to push past that pain in my chest  that has no name, nor chapter in any book.   Komorebi Scott nudges my kayak away from the shore.   The yellow plastic scrapes the sand and seashell bottom  until it glides to the open water, over deep-green seaweed that waves its version of goodbye.    A soft pushing away  a departing of one world, only to enter another,  so vast there are no names for things:   When I die  let it be like this.   Some languages have words for words we never even thought to speak.   In Japanese, for instance, there is a word  for the sunlight filtering through the leaves of a tree.   Tell me, why isn't there a name for this: The ocean's soft  pull, the gentle begging it does,      like a child tugging  at the tail of your shirt,    reminding you it's time to go.   Riches  As I cradle my morning tea I watch her from the window.   Crouched down in the yard, with her hand outstretched. Even   from here I see the arthritis knot and bend her fingers   from years of knitting intricate sweaters and working late-night shifts at the hospital.   The chickens come to her  hesitantly, to peck the scratch from her warm hand.   She told me once that even when  she has nothing to give them   they still peck softly at her wedding band.   They surround her now, their bobbing and dipping beaks   and as they take the seeds she offers,  she smooths the long yellow feathers   that in the right light turn golden.   If I could inherit a single thing from her it would be this patience,   this trust that life will come to you even when your body    is leaving this world slowly, one cell at a time.

In This Episode...Frost Protection: Peter shares an essential seasonal tip on laying fleece over your newly planted crops to shield them from late-season frost.Microgreens & Salads: David discusses his progress with microgreens and his method for planting Basil as a microsalad crop.Carrot Success: We explore the unique benefits of growing Carrots in pots for better pest control and root quality.Broad Bean Tapenade: Peter reveals his favourite recipe for a broad bean tapenade—the perfect way to use your harvest.Upcoming Events & FeaturesKew Gardens Orchid Festival: Taking place from 7 February to 8 March 2026, this year's Kew Gardens Orchid Festival celebrates Chinese biodiversity with stunning displays in the Princess of Wales Conservatory.Thriplow Daffodil Weekend: Don't miss this iconic event on 21st and 22nd March 2026. Tickets are available on the Thriplow Daffodil Weekend and often sell out early.Marathon For a Cause: Our Head Chef, Josh, is running the London Marathon on Sunday, 26 April 2026, to raise vital funds for Cystic Fibrosis.Special Guest: Manos KanellosJoin us on Saturday morning, 21st March, for a special talk by orchid expert Manos and in the afternoon for a class on how to create a Terrarium (tickets needed)Topics for discussion during the morning:Bring Your Orchid: If you have an orchid at home, bring it along for expert advice!Expertise: Manos works for Growth Technology, a specialist company that has spent years driving the orchid industry forward with high-quality products.Must-Read Book: He is also the co-author of the highly acclaimed book, "Growing Orchids at Home", published by the Royal Botanic Gardens, Kew. Hosted on Acast. See acast.com/privacy for more information.

“Patients are waiting…”Those simple but profound words from Dr. Steve St. Onge set the tone for this conversation, and for why this work matters so deeply.Science has always fascinated me. I often joke that I'm not smart enough to be a scientist, but I have endless respect for the people who are, especially those who can take incredibly complex ideas and explain them in a way the rest of us can truly understand. This is why I know you're going to love my conversation with Dr. St. Onge. Steve is the Chief Business Officer at Clarametyx. Dr. St. Onge is a PharmD and MBA with more than 15 years of experience spanning clinical care, medical affairs, and leadership in biotechnology. What stands out most about Steve isn't just his impressive résumé, it's his ability to clearly explain the science, the strategy, and, most importantly, the urgency behind the work Clarametyx is doing.I first met Steve in person at the North American Cystic Fibrosis Conference (NACFC) in Seattle, where we had the opportunity to really connect and talk about Clarametyx's approach. Their work focuses on targeting biofilm-driven inflammation and progressive lung damage, an area of significant unmet need for people living with chronic respiratory diseases, including cystic fibrosis. In this conversation, Steve breaks down what biofilms are, why they're so difficult to treat, and how Clarametyx is thinking differently about tackling the inflammation and lung damage they cause.We also talk about the long road of drug development, the responsibility that comes with working in rare disease, and why the phrase “patients are waiting” isn't just a saying, it's a call to action. This episode is an honest, accessible, and hopeful look at science in motion, and at the people behind the research who are driven by the patients counting on progress.If you've ever wanted a clearer understanding of how innovative science moves from idea to impact—and why time matters so much, his is a conversation you won't want to miss. Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

Send a textMorning Prayer (God Giver Of Life; Asthma/ COPD / Cystic Fibrosis; Government Leaders; Praise The LORD)Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

Sure, it's court-mandated...but we still give it our best shot! It's Feel Good Friday!

Dr. Charlotte McKee, Chief Medical Officer at Sionna, describes the nature of cystic fibrosis (CF, a genetic disease caused by a mutation in the single CFTR gene. While current CFTR modulator therapies do not address the most common mutation, Sionna's novel oral medicine is designed to target the previously undruggable NBDI domain of the CFTR protein. This new therapy aims to lead to better lung function and prevent the accumulation of permanent damage to other organs like the pancreas, gut, and liver.  Charlotte explains, "Cystic fibrosis is a genetic disease. The gene was actually discovered in 1989 for cystic fibrosis. It's considered a rare disease, but it's a relatively large rare disease. And one of those rare diseases that is potentially fatal, as you mentioned, it's thought of as a lung disease. And most patients, if their life is shortened, it's typically because of lung disease, because the lungs can be very severely affected. But the protein is caused by a genetic mutation in a gene called CFTR, and the protein is made from that gene. The CFTR protein is present on every epithelial cell of the body."   "Sionna is focused on a novel target in the CFTR protein. So you may know that, actually, there are approved medicines that have been developed over the last couple of decades that improve the function of the CFTR protein. And they've really advanced the clinical field, and there have been tremendous advances for people with CF. But this protein, this CFTR protein that goes wrong in CF, is a big, complicated, multi-part channel."   "Another unusual thing about CF is that there's one mutation that's so common around the world, and the part of CFTR that goes most wrong with F508del. This mutation is in a part of CFTR that was previously considered undruggable. It's that part that is called NBD1, and Sionna has been working for over a decade and a half of research, actually starting with Genzyme and then continuing through the company, Sanofi, has actually figured out how to develop potential medicines against this part of the CFTR protein that goes most wrong. And so we are working on these, they're called modulators, CFTR modulators, or we are working on NBD1-focused potential medicines that can directly bind to and stabilize this specific part of the CFTR protein."   #Sionna #CysticFibrosis #NBD1Stabilizers #CFTRModulators #RareDisease #Biotechnology #MedicalInnovation #PrecisionMedicine #GeneticDisease #PulmonaryHealth sionnatx.com Download the transcript here

Dr. Charlotte McKee, Chief Medical Officer at Sionna, describes the nature of cystic fibrosis (CF, a genetic disease caused by a mutation in the single CFTR gene. While current CFTR modulator therapies do not address the most common mutation, Sionna's novel oral medicine is designed to target the previously undruggable NBDI domain of the CFTR protein. This new therapy aims to lead to better lung function and prevent the accumulation of permanent damage to other organs like the pancreas, gut, and liver.  Charlotte explains, "Cystic fibrosis is a genetic disease. The gene was actually discovered in 1989 for cystic fibrosis. It's considered a rare disease, but it's a relatively large rare disease. And one of those rare diseases that is potentially fatal, as you mentioned, it's thought of as a lung disease. And most patients, if their life is shortened, it's typically because of lung disease, because the lungs can be very severely affected. But the protein is caused by a genetic mutation in a gene called CFTR, and the protein is made from that gene. The CFTR protein is present on every epithelial cell of the body."   "Sionna is focused on a novel target in the CFTR protein. So you may know that, actually, there are approved medicines that have been developed over the last couple of decades that improve the function of the CFTR protein. And they've really advanced the clinical field, and there have been tremendous advances for people with CF. But this protein, this CFTR protein that goes wrong in CF, is a big, complicated, multi-part channel."   "Another unusual thing about CF is that there's one mutation that's so common around the world, and the part of CFTR that goes most wrong with F508del. This mutation is in a part of CFTR that was previously considered undruggable. It's that part that is called NBD1, and Sionna has been working for over a decade and a half of research, actually starting with Genzyme and then continuing through the company, Sanofi, has actually figured out how to develop potential medicines against this part of the CFTR protein that goes most wrong. And so we are working on these, they're called modulators, CFTR modulators, or we are working on NBD1-focused potential medicines that can directly bind to and stabilize this specific part of the CFTR protein."   #Sionna #CysticFibrosis #NBD1Stabilizers #CFTRModulators #RareDisease #Biotechnology #MedicalInnovation #PrecisionMedicine #GeneticDisease #PulmonaryHealth sionnatx.com  Listen to the podcast here  

"Ever moment, every day is worth celebrating." Somer LoveSomer Love has spent her life choosing hope, dreaming big, and showing up fully for each day. Diagnosed with cystic fibrosis at just 11 months old, Somer has grown into a powerful and compassionate advocate for the CF community.Guided by her belief that “Every moment, every day is worth celebrating,” Somer brings joy and purpose into everything she does. She often reminds others that “laughter is key,” a mindset that has helped carry her, and those around her, through the challenges of life with cystic fibrosis.Through her work, Somer is dedicated to raising awareness, educating others, and offering hope, especially to families navigating a new CF diagnosis. In 2001, she founded Love to Breathe®, a platform created to educate, spread awareness about cystic fibrosis, and share love and connection around the world.Big on birthdays, Somer's parents made celebration part of her story in an unforgettable way. Every year, they placed Somer's photo on a billboard. What began as a birthday tradition became something much bigger, raising awareness about cystic fibrosis in a way that stops people in their tracks. What that billboard did for awareness will give you chills. It's something you will never forget. You'll have to listen to the podcast to hear the story!Somer knows that fighting CF isn't something anyone can do alone. Her journey is deeply rooted in the strength of her support system and the community that stands beside her. She continues to advocate not only for her own future, but for a cure, for everyone living with cystic fibrosis.Somer sums up the reason to advocate. This quote is on her website: "The goal isn't to live forever, but to create something that will"-Chuck Palahniuk Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

On this episode of The Mark White Show, I sit down with Coleman Drew, who was diagnosed with cystic fibrosis at just two years old. For most of his life, Coleman has faced daily treatments, hospital stays, and the quiet strength required to manage a chronic illness. Now, transplant has entered the conversation, and his family has partnered with COTA, the Children's Organ Transplant Association, to help with transplant-related expenses. This is not just a story about illness. It's a story about perseverance, faith, family, & the power of community support. Join us as Coleman shares what it has been like to grow up with CF, what this season looks like, & how you can stand with him in the fight. Learn how to support Coleman at: https://cota.org/cotaforcolemansfight/

95% of parents abort their unborn children for Cystic Fibrosis, but here's one of the 5%: she wasn't aborted and used her faith to turn adversity into hope, purpose, athletic excellence and a devotion to Christ.

When Insurance Gets Between Doctors and PatientsDr. Elizabeth Ames and Dr. Caleb Bupp are deeply committed to their patients. But like so many clinicians today, they're spending an extraordinary amount of time battling insurance companies instead of practicing medicine.Between prior authorizations, step therapy requirements, and outright coverage denials, physicians and their teams are buried in paperwork, often at the direct expense of patient care. Time that should be spent listening, diagnosing, and treating is instead consumed by forms, phone calls, and appeals.Boston Globe reporter Jonathan Saltzman raised the concern and Dr. Ames brought it to my attention. The reporter talks about, a new program rolled out by Blue Cross Blue Shield of Massachusetts. The insurer says the initiative is designed to control rising healthcare costs for its 3 million members, noting that costs have increased by 30 percent since 2021. But, the program specifically targets physicians who bill for the most expensive visits. The reason for the increased expense, which is discussed in our podcast, is because doctors are choosing to spend more time with rare disease patients who have complicated health issues. They need to spend more time with complex medical needs patients than say, someone with a sore throat.Drs. Ames and Bupp warn that this approach fundamentally misunderstands patient care, particularly for those with complex or rare conditions. “These patients don't need less time; they need more” says Dr. Ames. Physicians argue that policies like this risk rushed appointments, strained doctor/patient relationships, and poorer outcomes. Nowhere is this more concerning than in the rare disease community, where delays and denials can be devastating.Dr. Elizabeth Ames and Dr. Caleb Bupp talk about what this looks like in real life. As pediatric geneticists, they see firsthand how insurance barriers impact families already navigating diagnostic odysseys, uncertainty, and fear. Their work sits at the intersection of cutting-edge science and deeply human stories, and insurance interference often disrupts both. Dr. Ames, “Usually we get faxes saying, this has been denied and we start working on it. But the family gets a letter that the drug they need, the process is delayed by a “no”. We try and have good communication and say, “hey, we got this denial,” we're working on it. But I think it's deaths by a thousand cuts for the family. Families take the denial as, “I'm not worth of coverage, and that's really hard”. Dr. Bupp says they have had to hire genetic counselors, a job that didn't exist even 5 years ago, “We have a job description in our organization for it now because of the complexities that come with trying to unravel these insurance situations”.We should also note that Dr. Ames, Dr. Bupp, and I all serve on the Rare Disease Advisory Council (RDAC) in Michigan. “I think rare disease advocacy, there is power in numbers. One person can be a huge difference maker, but it's not one plus one equals two. It really exponentially grows, and I think with things like rare disease advisory councils, that gives you a better connection within your state, for state government and for advocacy. And I also think, or I hope, that it gives a place for an individual to plug in and that can then magnify and amplify. their voice so that they're not alone”. Many states have RDAC's, You can see if your state has an RDAC. For more on the Michigan RDACIn this article and in the podcast we are not speaking on behalf of the council, but it's important to understand why bodies like RDAC exist in the first place. Michigan is home to approximately one million people living with rare diseases, and the RDAC was created to ensure their voices, and experiences help shape policy. RDAC meetings are open to the public, and anyone in Michigan can participate and offer public comment. We hope you join our meetings via zoom (sometimes hybrid).This conversation isn't just about insurance policies. It's about time, trust, and whether our healthcare system truly serves patients, especially those with the most complex needs. Speak up, share your story. Advocate. Make a difference, Mold the future, for future generations.To look at the Everylife Diagnosis Odyssey https://everylifefoundation.org/delayed-diagnosis-study/ discussed in the podcast.  Everylife impact of diagnosis: https://everylifefoundation.org/burden-study/ Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events shaping the landscape of drug development, regulatory scrutiny, and industry advancement. As we navigate this complex terrain, we'll explore how these changes impact both companies and patients.In recent news, Moderna has encountered a substantial hurdle as the FDA declined to review its flu vaccine candidate, mRNA-1010. This decision marks a notable shift from the expedited processes witnessed during the COVID-19 pandemic, reflecting a more cautious regulatory approach under current administrative leadership. Analysts suggest this could indicate broader regulatory changes that might affect future vaccine approvals. Moderna's situation is emblematic of the challenges companies face in maintaining momentum post-pandemic, especially as their research and development spending saw a significant decrease of 31% last year due to completed respiratory trials. This reduction highlights a strategic pivot as the company reassesses its priorities amidst an evolving market landscape.Vertex Pharmaceuticals is making headlines with its ambitious revenue goals outside its established cystic fibrosis franchise. By 2026, Vertex aims to generate $500 million from non-CF medications, with recent launches like Casgevy and Journavx already showing promise by collectively bringing in $175.6 million last year. This diversification strategy is critical for mitigating risks associated with dependence on a single therapeutic area and reflects a broader industry trend towards strategic realignment. Additionally, Vertex remains under close observation within kidney disease portfolios, particularly with Povetacicept—an IgA nephropathy treatment—and the success of Journavx impacting market positions by offering chronic kidney disease patients new therapeutic options.PTC Therapeutics has faced setbacks with its FDA application withdrawal for Translarna, intended for treating nonsense mutation Duchenne muscular dystrophy. The decision came after receiving adverse feedback from the FDA, highlighting the complexities involved in gaining approval for therapies targeting intricate genetic conditions. Such hurdles underscore the high-risk nature of biotech ventures that are heavily reliant on regulatory timelines.Novartis is pushing forward with plans to seek full FDA approval for Vanrafia, its IgA nephropathy drug, despite not meeting primary kidney function goals in Phase 3 trials. This move aligns with a growing trend where companies pursue approval based on secondary endpoints or other supportive data when primary outcomes fall short. Such strategies underscore the competitive and high-stakes environment surrounding drug approval pathways.Novo Nordisk is expanding its production capabilities in Ireland to meet increasing demand for Wegovy, their obesity drug that's seen impressive sales in the U.S. This investment underscores the global potential for obesity treatments and highlights how manufacturing expansions are pivotal to supporting international market entry.In Europe, Amgen has secured approval for Uplizna in treating myasthenia gravis, adding another option to an already crowded treatment landscape but offering patients additional therapeutic choices. Meanwhile, AbbVie has launched a legal challenge against Botox's inclusion in drug pricing negotiations under the Inflation Reduction Act (IRA), arguing it should be excluded due to its plasma-derived nature.Ultragenyx has announced a 10% workforce reduction amid halted gene therapy plans and unsuccessful late-stage trials in brittle bone disease. These adjustments often reflect broader strategic shifts within biopharma companies as they realign focus and resources. Ultragenyx's operational challenges highlight the volatile nature of biotech ventureSupport the show

In this episode of the Clinical Research Coach, I sit down with Ella Balasa, a cystic fibrosis patient advocate whose lived experience is shaping how our industry understands trust, transparency, and meaningful patient engagement.Diagnosed in infancy with cystic fibrosis, a progressive genetic lung disease, Ella has spent her life navigating hospital systems, breakthrough therapies, and clinical trials — not as an abstract participant, but as someone whose health and future depend on research progress. Along the way, she has become a powerful voice for improving how industry partners with patients.In this conversation, Ella shares what sponsors, sites, and biotech leaders often overlook:* Patient experience is never one-size-fits-all — even within the same diagnosis.* Patients learn about trials through trusted networks, not just databases or digital ads.* Transparency builds confidence and drives long-term participation in research.* Dropout affects more than timelines — it influences trust and future enrollment decisions.* Technology should support patients, but never replace human connection.Ella's perspective challenges us to think beyond enrollment metrics and toward something deeper: relational trust. Because sustainable progress in clinical research depends on listening to patients as individuals, partners, and experts in their own lives.To learn more about Ella:Https:/ellabalasa.com

Innovating Medicine: How Science, Collaboration, and Curiosity Transform Patient CareIt is always inspiring to speak with true innovators on this podcast, the people who don't just follow the science, but actively push it forward, turning ideas into real-world solutions that change lives. We are honored to welcome Dr. Jeffry Weers whose work has profoundly impacted the cystic fibrosis (CF) community and beyond.Dr. Weers is a distinguished pharmaceutical scientist with more than 35 years of experience designing and developing novel drug-delivery systems. Throughout his career, he has focused on innovative treatments for CF, working across formulations, biologics, small molecules, and combination products. His achievements include an extensive patent portfolio and a remarkable publication record, but what truly sets him apart is his ability to translate ideas into treatments that improve patient lives.  I found that many scientists like Dr. Weers are soft spoken. They don't want to brag about their scientific successes, they just want their work to speak for itself.  Dr. Weers is so darn smart!  He won't toot his own horn, so I must!  He's a great person who is filled with so much hope for the future.One of Dr. Weers' most notable contributions is the invention of the Tobi Podhaler, a device that transformed how inhaled antibiotics reach the lungs. For people living with CF, this innovation has meant more effective, easier-to-administer treatment, significantly improving daily quality of life. His work exemplifies the power of scientific innovation to directly impact patient care.Dr. Weers delves into both the breakthroughs and the challenges of drug development. He shares insights into the ongoing hurdles of developing inhaled medications, including inhaled insulin, and emphasizes the regulatory obstacles that can slow the introduction of new anti-infectives. Yet, he remains optimistic about the future, highlighting the role of collaboration among scientists and the potential of AI to enhance medical imaging, diagnosis, and patient outcomes.Dr. Weers also stresses the critical importance of addressing infectious diseases in CF patients and the responsibility of the scientific community to advocate for better treatments. Beyond his professional achievements, he reflects on the personal side of being a lifelong scientist, sharing how interests like farming provide balance and perspective in a demanding career.I particularly loved recording this episode because Dr. Weers has a rare ability to make complex science accessible, explaining the “why” behind innovations in a way anyone can understand. For anyone curious about the intersection of science, medicine, and human impact, this conversation is both enlightening and inspiring.To watch a fabulous video that explains the creation of what it takes to get medicine into the lungs, view here: You Tube link: https://www.youtube.com/watch?v=fwglM8Zo4m0Inhaled drug delivery in CF/ YouTube link: nother YouTube link: https://youtu.be/iV27VdieQbo Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

Send us a textJoin Alex Rutledge and Red Bone for an in-depth exploration of the National Wild Turkey Federation (NWTF) - America's greatest conservation success story. In this special episode, we dive into the fascinating history of how one man's vision in 1972 transformed wild turkey populations from near extinction to thriving across all 50 states.We discuss the upcoming NWTF National Convention in Nashville, featuring over 80,000 attendees, celebrity appearances including Craig Morgan, and the historic 50th anniversary exhibit. Plus, we share personal turkey hunting stories, discuss current weather impacts on wildlife, cover local sports updates, and wrap up with delicious wild turkey recipes you can try at home.Whether you're a seasoned turkey hunter or just curious about conservation, this episode celebrates the heritage, community, and passion that makes turkey hunting a cherished American tradition.Chapter Markers:[0:00] Introduction & Weather UpdateSnow and ice conditions in the OzarksSafety reminders for winter weatherMDC tree stand regulations and spring turkey hunt applications[7:30] Current Events: Sports RoundupHigh school basketball updates (Liberty, Van Buren, Bunker Eagles)College basketball highlights and faith testimoniesNFL playoff predictions and Super Bowl preview[15:45] Craig Morgan Concert AnnouncementMarch 21st Cystic Fibrosis fundraiser at West Plains Civic CenterTicket information and Craig Morgan's military promotion[18:20] NWTF National Convention PreviewNashville convention details (February)80,000+ attendees expectedHistoric 50th anniversary exhibitCelebrity appearances and Grand National Turkey Calling Competition[22:15] The Beginning: NWTF History (Part 1)Wild turkey population crisis (1.3 million birds in 1972)Federal legislation: Lacy Act, Migratory Bird Treaty Act, Pittman-Robertson ActCannon net technology revolutionTom Rogers' vision for a national organization[32:40] The Founding: NWTF History (Part 2)Tom Rogers meets key supporters (Frank Piper, Jerry Ones, John Lewis)March 28, 1973: NWTF chartered in Fredericksburg, VirginiaMove to Edgefield, South Carolina with "$10,000 and a cigar box of membership cards"First headquarters established[40:25] NWTF Impact & MissionResearch and conservation effortsDisease prevention and wildlife managementImportance of membership and chapter involvementCurrent River Callers chapter raises over $40,000[48:50] Personal Stories & Convention ExperienceAlex's introduction to NWTF in 1981 by Glen CadeHistory of turkey calling evolutionWhy families should attend the Nashville conventionMeeting celebrities and professional hunters[56:30] Conservation PhilosophyGetting kids involved in the outdoorsEthical hunting and land stewardshipSupporting NRA, Sportsman's Alliance, and conservation organizationsPassing heritage to future generations[1:02:15] Bonus Segment: Wild Turkey RecipesRed Bone's smoked turkey breast technique (with moisture pan method)Alex's turkey nuggets with buttermilk marinadeTurkey salad sandwich spread from dark meatTips for using the entire bird[1:08:30] Closing ThoughtsTurkey hunting camp opportunities in Ohio, Missouri, and AlabamaFinal message: "Love one another, teach your boys to become men, teach your girls to become ladies"

Daelyn James, is someone who understands the power of owning your story. Diagnosed with cystic fibrosis at just four years old, she remembers what it felt like to go from a carefree childhood to one filled with treatments, doctor visits, and a reality she wasn't ready to face. For a long time, Daelyn kept her CF hidden because she was worried it would change how people saw her or limit what she could do.But in high school, everything shifted. Daelyn made the brave decision to stop running from her diagnosis and start embracing it as part of who she is. And that choice changed her life.Now 25, she proudly lives with CF and uses her experiences to raise awareness, connect with others, and offer hope. Her message is simple but powerful: even in the hardest moments, there is strength, there is goodness, and there is always a way forward.I'm so excited for you to hear her story.To connect with Daelyn visit her on IG: https://www.instagram.com/daelyn_j/To connect with Somer Love her IG is Love to Breath: https://www.instagram.com/lovetobreathe/ Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

Running for Time: Chad Eddy's Mission Against Cystic FibrosisFor Chad Eddy, the fight against cystic fibrosis isn't abstract, it's personal. He's the proud uncle of two nieces born with CF. One is still living.When his goddaughter was born in 1998, (he asked their names not be used) the second of his nieces diagnosed with cystic fibrosis, Chad's world changed. He quickly realized that simply walking in charity events or asking friends and family to donate wasn't enough. Love demanded action. Hope demanded movement.He wanted to do more. He wanted to be part of the generation that finds the cure. It's his motto.In 2017, Chad's heart broke when one of his nieces lost her courageous fight with CF. But even in grief, he found his purpose. He made a promise to her, and to his living niece, and to every person living with CF, that he would keep running toward a cure.Now, Chad isn't running for a medal. He's running for time. Time for those who can't breathe freely. Time for families waiting on a cure. Time for the breakthroughs that can change everything.His mission has taken shape in an extraordinary endurance challenge: running 6.5 miles every 6.5 hours for 65 straight hours , all to raise $65,000 for cystic fibrosis research.This is not a race. It's a test of heart, exhaustion, and purpose, run one step, one story, one promise at a time.Already, more than 80 donors have stepped forward, contributing over $11,000 to support Chad's mission. But this is no longer just a personal challenge, t's a movement.Through a short documentary film, that movement, and its heartbeat, will be captured forever.For everyone still fighting for breath, Chad runs because every moment counts. And he won't stop until cystic fibrosis is a disease of the past.For more information and to donate:: https://fundraise.cff.org/roseup2025/65milesin65hoursforCF To see the trailer for Generation: Cure: https://youtu.be/YyI_rNXuNAI?si=pk_tBY3NZkdtdfTn Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

Very young children with cystic fibrosis could soon access funded medicines with the potential to add decades to their lives. Christchurch couple Edward and Emily Harrington-Ashton's 20 month-old- son, Noah, has cystic fibrosis. They say the drug will be life changing for their son. Edward spoke to Lauren Crimp.

Families of young children with cystic fibrosis are celebrating a Pharmac proposal to widen access to the drug Trikafta, which is out for consultation. It's been funded for children over 6 since 2023, but the agency's now proposing extending it to under-sixes. Liam Rooney's child has cystic fibrosis and he says his family was looking for other ways to get it. "I'd already spoken to my boss over in Australia about the potential for us to move over if things got worse." LISTEN ABOVESee omnystudio.com/listener for privacy information.

When Jennifer joined New Hope in 2018, she didn't just take a job — she stepped into a calling. What began as a role coordinating outreach and events quickly became a mission to change how communities understand and support grief. With her compassion, creativity, and drive, Jennifer helped New Hope grow from a local resource into a lifeline for families across the region. Her leadership was soon undeniable — first as Interim Executive Director, then officially taking the helm in January 2020 — guiding New Hope through seasons of transformation, expansion, and profound impact.Under Jennifer's direction, New Hope has launched new loss-specific grief groups, expanded programming, and reached grievers in more communities than ever before. She continues to build on her expertise through national training with the National Alliance for Children's Grief and other organizations, ensuring that every program New Hope offers is trauma-informed, compassionate, and deeply effective.Jennifer's community involvement runs wide and deep — she serves on multiple local health and wellness councils, partners with school districts, and facilitates leadership and family development programs, includingThe Leader in MeandThe 7 Habits of Highly Successful Families. She's also been invited to speak and moderate at events like Hegira Health'sFocus on Zerosuicide prevention conference, sharing insights on resilience and healing.Today, Jennifer not only leads New Hope but helps train other organizations on how to support those in grief. She's currently helping design age-specific grief curriculum for students — empowering young people to understand loss, express emotion, and find hope. She's seen the full circle of healing firsthand: those once supported by New Hope returning to offer that same compassion to others, creating a community where no one grieves alone. Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

In this final deep dive episode, Stuart Elborn turns to healthcare systems and policy. He discusses the importance of registries, data sharing, and service organisation, alongside social and funding factors that shape equitable cystic fibrosis care, ending with a global vision for cystic fibrosis management over the next decade. Timestamps: 00:00 – Introduction 01:08 – Healthcare delivery 03:33 – National registries 05:04 – New challenges 06:35 – Equitable care 08:51 – Regional initiatives 10:40 – What's next?

In this second deep dive episode, Stuart Elborn explores the future landscape of cystic fibrosis treatment beyond modulators. From mRNA and gene editing to inhaled therapies and phenotype-driven care, this episode examines how close we are to truly personalised medicine in cystic fibrosis.  Timestamps: 00:00 – Introduction 01:22 – Treatment gaps 03:13 – Extrapulmonary complications 04:14 – Novel therapies 06:04 – Delivery routes 07:33 – Personalised medicine

A black leather jacket, black hoop earrings, black T-shirt and pants. You may visualize a rock star, and Colin Hemez is a rock star of sorts, but he actually works in a white coat, a doctors coat. Yes, he's a scientist.Dr. Hemez brings a remarkable blend of science, creativity, and purpose to the fight against cystic fibrosis. Colin was born in France and raised in the high-desert town of Los Alamos, New Mexico, an environment steeped in scientific discovery. Summers interning at Los Alamos National Laboratory sparked his early fascination with how innovation can change lives.At Yale, he explored the intersection of engineering and art, studying biomedical engineering alongside art history to understand both the precision of science and the elegance of design. But it was a research trip to the Arctic University of Norway that set his path in motion. While building mathematical models of antibiotic resistance, a challenge many people with cystic fibrosis face, Colin discovered his true calling.Today, he's a PhD student in Dr. David R. Liu's renowned laboratory at Harvard, working at the cutting edge of gene editing for cystic fibrosis. Every day, Colin is pushing boundaries, imagining a future where science doesn't just treat CF but has the power to rewrite its story.We had to so much fun talking in this podcast. Born in France we talk about Colin's wonderful siblings and parents. They're all incredibly smart and making a huge difference in our world.Outside the lab, Colin reflected on the grounding role of art, music, and outdoor exploration, coping mechanisms that keep him connected to the world he's trying to impact. Looking ahead, he's both hopeful and driven: gene editing for cystic fibrosis is no longer a distant dream but a rapidly approaching reality with global implications. His aspirations are bold, but so is the science.In his view, the future of CF research depends on collaboration, imagination, and staying rooted in why the work matters: to bring healthier, longer lives within reach for every person living with this disease. We sure love his passion for science. You won't want to miss this Amazing Podcast. To watch Colin's PhD  https://drive.google.com/file/d/1HizIGiqGdKDgIifT7HF9t0UDVgv0tOKE/view Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

In this first deep dive, Stuart Elborn reflects on the major scientific breakthroughs of his career, and how laboratory discoveries have transformed cystic fibrosis care. He discusses lessons from pivotal CTFR modulator trials, the role of consensus guidelines, and the challenges of caring for an ageing cystic fibrosis population.

Stuart Elborn joins the EMJ Podcast for a quickfire discussion on modern cystic fibrosis care. From CFTR modulators to antimicrobial resistance and personalised medicine, he shares concise insights into the biggest shifts shaping cystic fibrosis outcomes today.

This week’s Pulm PEEPs Pearls episode is a focused discussion between Furf and Monty about non-pharmacologic techniques for airway clearance in the non-Cystic Fibrosis bronchiectasis population. This is a focused, high-yield discussion of the key points about airway clearance, including practical tips and a discussion of the evidence. This episode was prepared in conjunction with George Doumat MD. Goerge is an internal medicine resident at UT Southwestern and joined us for a Pulm PEEPs – BMJ Thorax journal club episode. He is now acting as a Pulm PEEPs Editor for the Pulm PEEPs Pearls series. Key Learning Points 1) Why airway clearance matters in non-CF bronchiectasis Non-CF bronchiectasis is defined by irreversible bronchial dilation with impaired mucociliary clearance, leading to mucus retention. Retained sputum drives the classic vicious cycle: mucus → infection → neutrophilic inflammation → airway damage → worse clearance. Airway clearance techniques (ACTs) are meant to interrupt this cycle, primarily by improving mucus mobilization and symptom control. 2) What ACTs are trying to achieve clinically Main benefits are: More effective sputum clearance Reduced cough/dyspnea burden Improved activity tolerance and quality of life Effects on spirometry are usually small. Exacerbation reduction is possible, but evidence is mixed—some longer-term data suggest benefit for specific techniques. 3) The main ACT “families” and when to use them Breathing-based techniques (device-free, flexible) ACBT (Active Cycle of Breathing Technique): breath control → deep breaths with holds → huffing. Pros: portable, adaptable, good first-line option. Key requirement: teaching/coaching to get technique right. Autogenic drainage: controlled breathing at different lung volumes to move mucus from peripheral → central airways. Pros: no device, can work well once learned. Cons: more technically demanding, needs training and practice. PEP / Oscillatory PEP (stents airways + “vibrates” mucus loose) PEP: back-pressure helps prevent small airway collapse during exhalation; often paired with huff/cough. Oscillatory PEP (Flutter/Acapella/Aerobika): adds oscillation that many patients find easy and satisfying to use. Good fit for: people who benefit from airway stenting, want something portable, and prefer a device. Mechanical/manual techniques (help when patient can't self-clear well) HFCWO (“the vest”): external chest wall oscillation; helpful for high sputum volumes, dexterity limits, or difficulty coordinating breathing maneuvers. Postural drainage/percussion/vibration: caregiver/therapist-assisted options; still useful but consider: GERD/reflux risk with certain positions Hemoptysis risk with vigorous techniques 4) How to choose the “right” technique (the practical framework) There is no one-size-fits-all. Match the tool to the patient: Sputum burden (volume/viscosity) Strength, coordination, cognition, dexterity Comorbidities (GERD, hemoptysis history, severe obstruction/airway collapse) Lifestyle + portability (what they'll actually do) Cost/access and availability of respiratory therapy/physio support A key mindset from the script: this is not a lifetime contract—reassess and adjust over time with shared decision-making. 5) Evidence takeaways (what improves, what doesn't) ACTs reliably improve sputum expectoration and often symptoms/QoL. QoL/cough scores (e.g., SGRQ, LCQ) tend to improve modestly, particularly with oscillatory PEP and some vest studies. Lung function: typically minimal change; occasional short-term FEV₁ benefit is reported in some vest trials. Exacerbations: mixed overall; the script highlights a longer-term RCT of ELTGOL showing fewer exacerbations at 12 months vs placebo exercises. Safety: generally excellent; main cautions are hemoptysis and reflux (depending on technique/positioning). 6) Special population pearls Hemoptysis / fragile airways: start with gentle breathing-based ACTs (ACBT, controlled huffing); avoid overly vigorous oscillatory/manual methods if concerned. Severe obstruction or early airway collapse: PEP/oscillatory PEP can help by keeping small airways open on exhalation. Mobility/coordination barriers: consider HFCWO vest or simple oscillatory PEP devices to enable daily adherence. During exacerbations: keep it simple—1–2 reliable techniques, prioritize daily consistency, and re-check technique. 7) The “real” bottom line Start with simple, self-manageable options (often ACBT ± PEP). The “best” ACT is the one the patient will do consistently. Reassess technique and fit over time; education and demonstration are part of the therapy. References and Further Reading  Lee AL et al., “Airway clearance techniques for bronchiectasis,” Cochrane Database Syst Rev. 2015; PMC7175838. PMID: 26591003. Athanazio RA et al., “Airway Clearance Techniques in Bronchiectasis,” Front Med (Lausanne). 2020; PMC7674976. PMID: 33251032. Iacono R et al., “Mucociliary clearance techniques for treating non-cystic fibrosis bronchiectasis,” Eur Rev Med Pharmacol Sci. 2015; PMID: 26078380. Polverino E et al., “European Respiratory Society statement on airway clearance techniques in bronchiectasis,” Eur Respir J. 2023; PMID: 37142337. Doumat G, Aksamit TR, Kanj AN. Bronchiectasis: A clinical review of inflammation. Respir Med. 2025 Aug;244:108179. doi: 10.1016/j.rmed.2025.108179. Epub 2025 May 25. PMID: 40425105.

Breath to Breath Film that celebrates the contributions by Dr. Michael WelshA Conversation with Dr. Michael Welsh: The Science That is Saving LivesIt's always such a privilege to feature CF icons on the podcast. Over the years, we've been fortunate to host some of the most influential names in cystic fibrosis research, including Dr. Francis Collins, the former director of the NIH and one of the authors of the Human Genome Project, and his longtime friend Dr. Mitch Drumm, who was working on his doctorate when the CF gene was discovered back in 1989.I actually saw Mitch recently at a dinner, and as many of you know, Dr. Collins continues to be a tireless advocate for good science and for sharing its importance with the world.And now, we add another legend to that list: Dr. Michael Welsh from the University of Iowa.Dr. Welsh tells his story beautifully in the University's film Breath by Breath: Living with Cystic Fibrosis. In it, he describes how his curiosity about the CFTR protein led to groundbreaking discoveries that ultimately laid the foundation for CF therapies, the very treatments that have changed (and saved) thousands of lives, including the lives of my daughters.Dr. Welsh's career is extraordinary, spanning decades of research, mentorship, and discovery. He's the Carver Professor of Internal Medicine and Molecular Physiology and Biophysics at the University of Iowa, and from 1989 to 2024, he served as an Investigator with the Howard Hughes Medical Institute. He currently directs both the Pappajohn Biomedical Institute and the Cystic Fibrosis Research Center.We've linked both his full bio and the film in the show notes, and I highly encourage you to check them out. His accolades could fill pages, actually, an entire book! We had so many laughs too in this podcast! So much fun. You'll really enjoy it.Dr. Welsh shared insights not only into his scientific journey, but also the heart behind the work. He recently received the Lasker Award for pioneering CF research that led to life-saving therapies, a recognition that celebrates decades of persistence, curiosity, and collaboration.We discussed so much:How his team began unraveling the mystery of the CFTR protein and what that breakthrough moment felt likeWhat it's like to see patients thriving because of the treatments that grew from that workWhy the University of Iowa decided to produce Breath by Breath, and what the film means to him personallyWhat new treatments and discoveries he's exploring nowHearing Dr. Welsh describe the intersection of science, hope, and humanity is powerful. You can tell that for him, this work isn't just research, it's a mission.As the documentary shows, CF isn't just a disease studied under a microscope. It's a lived experience for patients and families, one that now includes real hope thanks to the breakthroughs made by scientists like Dr. Michael Welsh.Biography:Dr. Michael Welsh is the Carver Professor of Internal Medicine and Molecular Physiology andBiophysics at the University of Iowa. From 1989-2024, he was an Investigator of the HowardHughes Medical Institute. He directs the Pappajohn Biomedical Institute and the Cystic FibrosisResearch Center.Dr. Welsh obtained an MD and completed an internal medicine residency at the University ofIowa. He then trained in pulmonary medicine and research at the University of California, SanFrancisco and physiology at the University of Texas, Houston.Dr. Welsh and his colleagues discovered that the protein affected in cystic fibrosis is an anionchannel, elucidated its functional mechanisms, discovered ways that mutations disrupt function,and showed that mutations can be rescued. This work led directly to development of medicinesthat target CFTR and are highly effective for most cystic fibrosis patients. To understand diseasepathogenesis, he and his collaborators developed cystic fibrosis pigs, the first mammal, otherthan mice, in which a gene was targeted to generate a disease model.His clinical activities focused on pulmonary diseases. He has trained many physicians andscientists and received the Distinguished Mentor Award, University of Iowa Carver College ofMedicine.To watch the film, click here:  https://uihealthcare.org/cystic-fibrosis-research-iowa#documentaryTo learn more about Dr. Welsh: https://internalmedicine.medicine.uiowa.edu/profile/michael-welsh Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

Today's Case A 30-year-old nulliparous Caucasian woman comes in for her routine gynecology appointment. She tells you that she would like to discontinue her birth control as she and her partner are planning to become pregnant in the next year. The patient says that one of her family members has cystic fibrosis (CF). Today's Reader Dr. Kada Fehlman is an Internal Medicine Resident at Huntington Health Cedars-Sinai. About Dr. Raj Dr Raj is a quadruple board certified physician and associate professor at the University of Southern California. He was a co-host on the TNT series Chasing the Cure with Ann Curry, a regular on the TV Show The Doctors for the past 7 seasons and has a weekly medical segment on ABC news Los Angeles. More from Dr. Raj ⁠⁠⁠⁠⁠The Dr. Raj Podcast⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠Dr. Raj on Twitter⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠Dr. Raj on Instagram⁠⁠⁠⁠⁠ Want more board review content? ⁠⁠⁠⁠⁠USMLE Step 1 Ad-Free Bundle⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠Crush Step 1⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠Step 2 Secrets⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠Beyond the Pearls⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠The Dr. Raj Podcast⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠Beyond the Pearls Premium⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠USMLE Step 3 Review⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠MedPrepTGo Step 1 Questions⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠MedPrepTGo Step 2 Questions⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

  In this third and final deep-dive episode, Nicholas Simmonds highlights the importance of collaborative networks, such as the European Cystic Fibrosis Society (ECFS) Clinical Trials Network, in enabling global clinical trials. He also emphasises the central role of the patient voice in developing new therapies, using CFTR modulators as a key example. Timestamps: 00:00 – Introduction 00:55 – ECFS Network 03:29 – Trial design 04:54 – Therapy frontiers 07:48 – Curative approaches 13:07 – Clinician message

How is cystic fibrosis diagnosis evolving? In this second deep dive, Nicholas Simmonds explores advances in diagnostic tools and shares his experience with the CF registry, highlighting its value as a powerful resource for tracking long-term treatment effectiveness. A must-listen for clinicians and anyone interested in how cystic fibrosis is diagnosed, and how progress is monitored over time. Timestamps: 00:00 – Introduction 00:52 – Adulthood diagnosis 06:00 – Advanced diagnostics 10:37 – Survival variability 15:05 – CF Registry

Nicholas Simmonds joins host Saranya Ravindran for a deep dive into how adult cystic fibrosis (CF) care is evolving. Drawing on decades of experience, he discusses the major shifts in adult CF management, the vulnerable transition from paediatric to adult services, and strategies that ensure a smooth handover. Explore how longer survival brings new challenges, from fertility to mental health and emerging comorbidities, and why continuity of multidisciplinary care is more crucial than ever.  Timestamps: 00:00 – Introduction 01:15 – Adult care 04:12 – Smooth handover 10:10 – Evolving needs  

In this rapid-fire episode, Nicholas Simmonds answers key questions about cystic fibrosis (CF), from common misconceptions and the value of registry data to CF testing, and the transition from paediatric to adult care. Perfect for listeners short on time.

There have been great advances in the treatment of cystic fibrosis, but nevertheless it remains a progressive, life‑shortening genetic disease as many patients still don't reach normal function and continue to face infections, exacerbations, and impaired quality of life. Siona Therapeutics is building a new generation of small‑molecule therapies that directly stabilize the region most affected by the most common mutation underlying the disease for the roughly 90 percent of patients who carry the defect. We spoke to Mike Cloonan, CEO of Sionna, about its experimental therapy that stabilizes the misfolded protein at the heart of the disease, its exploration of combination therapies with existing and proprietary therapies, and its $219 million IPO in February, despite the difficult financing environment for development-stage biotechs.

How can the threat of antimicrobial resistance be mitigated? In this second deep-dive episode, Lisa Saiman shares insights into the value of antibiotic stewardship and the nuance of microbial susceptibility testing in patients with cystic fibrosis. A must-listen for anyone curious about the overlap between cystic fibrosis and pathogen resistance. Timestamps: 00:00 – Introduction 03:30 – Antimicrobial resistance threat 04:20 – Antibiotic stewardship 07:00 – Hospital lessons 10:00 – New antimicrobials

In the final instalment of this episode on paediatric cystic fibrosis, Lisa Saiman explores the global inequities that persist, noting how progress is hindered by limited access to advanced antimicrobial resistance prevention tools such as sequencing and pathogen identification. She emphasises the need for strengthened international collaboration to help bridge these gaps. Timestamps: 00:00 – Introduction  00:56 – Care inequities 03:30 – Global lessons 07:08 – Global collaborations 08:56 – Future directions

In this rapid-fire episode, Lisa Saiman answers key questions about infections in children with cystic fibrosis, from everyday prevention measures to the threat of antimicrobial resistance. Perfect for listeners short on time but eager to boost their paediatric cystic fibrosis knowledge in just a few short minutes.

Lisa Saiman joins host Saranya Ravindran to discuss infection prevention in children with cystic fibrosis, exploring evolving hospital and clinical practices, key respiratory pathogens, and practical strategies to reduce infection risk at home. Learn about how the risk of infection affects the day-to-day lives of patients with cystic fibrosis. Timestamps: 00:00 – Introduction 01:05 – Prevention importance 04:34 – International management 05:58 – Cross-infection risk 06:55 – COVID-19 lessons 07:43 – Home risk 10:57 – Childhood pathogens

Landon Carpenter is a volunteer in Blue student ministry. He sits down with Noisy Narratives to talk about how he met his wife, what it means to love and partner with a spouse with Cystic Fibrosis, and how he feels God prepared him for their life. Landon's perspective is encouraging and his story is a testament to God's faithfulness. Landon's wife, Angela, shared her story in an earlier season - you can listen here.PROGRAM NOTE - please pardon the audio issues during the intro. Equipment problems created some challenges - but we will have them fixed for next week. The interview audio is good!

 This Giving Tuesday, we have a special episode of the ATS Breathe Easy podcast. Wildfires are a destructive phenomenon that decimates communities, infrastructure, and wildlife. But wildfires and wildfire smoke are also severely damaging to human health, especially for those who have lung disease. Stacie Reveles, of the Cystic Fibrosis Research Institute, talks about her struggles living in wildfire country with a child who has cystic fibrosis. She discusses everything from dealing with medications and evacuations, the mental toll, and the importance of continued research into these illnesses. Air Health Our Health podcast creator Erika Moseson, MD, MA, of Legacy Health in Oregon hosts. Donate to the ATS Research Program today to help families like Stacie's: https://aeugmntn.donorsupport.co/page/Stacie The ATS Wildfire Disaster Guidance sheet: https://www.thoracic.org/patients/patient-resources/resources/wildfires.pdf  Listen to the Our Health in Wildfire Season episode of Air Health Our Health for how to prepare your home and community: https://creators.spotify.com/pod/profile/airhealthourhealth/episodes/Our-Health-in-Wildfire-Season-e162en9/a-a2ata11 

Please visit answersincme.com/KUS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonary medicine discusses the treatment of patients with non–cystic fibrosis bronchiectasis (NCFB) using dipeptidyl peptidase 1 (DPP1) inhibitors. Upon completion of this activity, participants should be better able to: Recognize the rationale for targeting neutrophilic inflammation in non–cystic fibrosis bronchiectasis (NCFB); Describe the clinical impact of DPP1 inhibitors for treating NCFB, in the context of conventional therapy; Outline strategies to individualize the selection of neoadjuvant, adjuvant, or perioperative immunotherapy approaches for patients with resectable stage IIB/C and stage III/IV melanomaApply strategies to enhance outcomes for patients with NCFB as the treatment landscape evolves; and Apply strategies to enhance outcomes for patients with NCFB as the treatment landscape evolves.

This is Part 2 of Josh and Amy Glasscock's story. We'll hear how Josh's cystic fibrosis has worsened and irreparably damaged his lungs. Soon, they'll be confronted with several life and death decisions. Only God will be able to carry them through the storms ahead. Listen to Part 1 in Episode #38 "Chronically Sick. Abundantly Alive. - Josh & Amy Glasscock, Part 1" Show notes: https://compelledpodcast.com/episodes/josh-amy-glasscock-pt-2 ++++++++++++ Compelled is a seasonal podcast using gripping, immersive storytelling to celebrate the powerful ways God is transforming Christians around the world. These Christian testimonies are raw, true, and powerful. Be encouraged and let your faith be strengthened! Want to help make new episodes? Either make a one-time gift, or become a Monthly Partner at: https://compelledpodcast.com/donate Perks of being a Monthly Partner include: EARLY ACCESS to each new Compelled episode 1 week early! FULL LIBRARY of our unedited, behind-the-scenes interviews with each guest... over 100+ hours of additional stories and takeaways! Become a Monthly Partner by selecting the "Monthly" option during check-out.  Show notes, emails, and more at: https://compelledpodcast.com Buy the Compelled book of testimonies, endorsed by Lee Strobel, Marvin Olasky, and more: ⁠https://compelledpodcast.com/book Compelled is a member of the Proclaim Podcast Network: https://proclaim.fm Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textJohnny and BW talk a bit about last weeks SEC win against Arkansas and preview this weeks game against the Georgia Bulldogs.   Then they are joined by Memphis' Action News 5 Anchor Joe Birch.  Joe helps support the Cystic Fibrosis foundation and many other local philanthropies in Memphis.  He talks a bit about how he ended up in Memphis and ultimately became a news anchor for channel 5.  He also discusses his involvement with the St. Jude Marathon.  Help support our cause to raise money for Cystic Fibrosis research by ordering a fresh roasted bag of coffee from Johnnypacker.netSupport the show

What's it like getting pepper-sprayed when you have a chronic lung disease? A homicide detective knows what's up. This week, we sit down with a guest who defies expectations: Jeremy, a homicide detective living with Cystic Fibrosis (CF). We dive into the unique challenges and surprising advantages of managing a demanding, high-stress career alongside a chronic illness. He opens up about the progression of his CF, the profound impact of the life-changing drug Trikafta, and his perspective on life expectancy before and after the medication. You can watch this entire episode over on YouTube.Follow Sickboy on Instagram, TikTok and Discord!